Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT06100393
Recruiting Not applicable

New Algorithms to Signal Processing for Speech Enhancement in Adult Cochlear Implant Recipients.

NCT06100393 · tracked via the Priya Life Science Australia tracker
Sponsor
Phase
Not applicable
Started
2024-02-22
Last updated
2026-08-14

Condition(s) studied

Hearing Loss

Investigational drug(s) / intervention(s)

Investigational Pre-Processing Algorithm (Sub A)Cochlear Limited standard-of-care pre-processing algorithmsInvestigational Pre-Processing Algorithm (Sub B)Investigational pre-processing algorithm (Sub D)Investigational Pre-Processing Algorithm (Sub C)Investigational Pre-Processing Algorithm (Sub E)

Investigational Pre-Processing Algorithm (Sub A): DNR algorithm

Cochlear Limited standard-of-care pre-processing algorithms: Standard-of-care sound path as implemented in the N8 system

Investigational Pre-Processing Algorithm (Sub B): Spatial Automation profile

Investigational pre-processing algorithm (Sub D): Microphone miscalibration profile with applied correction method

Investigational Pre-Processing Algorithm (Sub C): Spatial Automation profile and DNR algorithm

Investigational Pre-Processing Algorithm (Sub E): CUSP reference sound path

Study summary

The purpose of this clinical investigation is to develop pre-processing strategies to enhance speech and reduce noise for CI listeners. The Clinical Investigation will be comprised of several arms which will aim to optimize speech enhancement algorithms, to improve real-world functionality, and to incorporate them efficiently into CI speech processors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * User of an approved Nucleus cochlear implant. * User of the ACE (Advanced Combination Encoder) sound processing strategy. * Aged 18 years or older (no upper age limit). * Able to score 20% or more at +10 dB SNR or have an adaptive Speech Recognition Threshold (SRT) of 12 dB or less CI alone on a sentence in babble test.\* * Fluent speaker in the language used to assess speech perception performance, as determined by the investigator. * Willing and able to provide written informed consent. * ≥3 months post cochlear implant activation Exclusion Criteria: * Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator. * Additional health factors, known to the investigator, that would prevent or restrict participation in the audiological evaluations. * Investigator site personnel directly affiliated with this study and/or the investigator's immediate families; immediate family is defined as a spouse, parent, child, or sibling. * Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation. * Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Cochlear Melbourne Melbourne Victoria Recruiting
HEARnet Clinical Studies Melbourne Victoria Active Not Recruiting

More Cochlear trials in Australia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06100393 on ClinicalTrials.gov ↗ ← All trials in Australia